Showing 4461-4470 of 5957 results for "".
- Visibly Becomes First FDA-Cleared Online Vision Test in the United Stateshttps://modernod.com/news/visibly-becomes-first-fda-cleared-online-vision-test-in-the-united-states/2481033/Visibly, the developer of an at-home digital vision testing platform, announced that it has received 510(k) clearance from the FDA for its Visibly Digital Acuity Product (VDAP). Visibly said it is the first FDA-cleared online visual acuity test on the US market. View Eyew
- Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the Omni Surgical System in Patients with Open Angle Glaucomahttps://modernod.com/news/sight-sciences-announces-long-term-safety-and-effectiveness-data-of-standalone-use-of-the-omni-surgical-system-in-patients-with-open-angle-glaucoma/2481030/Sight Sciences announced 36-month post-surgery follow-up results of the Omni Surgical System. The data demonstrate that the OMNI Surgical System delivers safe, consistent, and durable results in adult patients with open-angle glaucoma (OAG) on a standalone basis, according
- CooperVision MiSight 1 Day Officially Launches in Chinahttps://modernod.com/news/coopervision-misight-1-day-officially-launches-in-china/2481026/CooperVision and EssilorLuxottica have officially launched MiSight 1 day contact lenses in China, marking its availability in the world’s largest country for myopia management. It is the first product of any type that has an indication from the Chinese National Medical Products Adminis
- Clearside Biomedical Enters Into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for Up to $65 Millionhttps://modernod.com/news/clearside-biomedical-enters-into-non-dilutive-financing-agreement-with-healthcare-royalty-partners-for-up-to-65-million/2481020/Clearside Biomedical announced it has entered into an agreement with HealthCare Royalty Partners in a deal worth up to $65 million. Clearside intends to use the proceeds from the agreement to support ongoing clinical development of its pipeline, including CLS-AX (axitini
- Study: Neurolenses Have Significant Impact on Reading Speedhttps://modernod.com/news/neurolenses-have-significant-impact-on-reading-speed/2481017/As has been demonstrated by many studies, contoured prism has historically shown efficacy in relieving symptoms as a therapeutic offering. And new evidence suggests that there is also an opportunity to expand this technology to an even broader population focused on visual performance and producti
- Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Diseasehttps://modernod.com/news/tarsus-initiates-phase-2a-ersa-trial-evaluating-tp-03-for-the-treatment-of-meibomian-gland-disease/2481015/Tarsus Pharmaceuticals announced that it has enrolled the first patient in a phase 2a clinical trial studying TP-03 (lotilaner ophthalmic solution, 0.25%) for the treatment of meibomian gland disease (MGD) in patients with Demodex mites. Demodex
- FDA Approves First Biosimilar Interchangeable to Lucentishttps://modernod.com/news/fda-approves-fyb201cimerli-the-first-and-only-biosimilar-to-lucentis/2481012/Coherus BioSciences announced that the FDA has approved Cimerli (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis (ranibizumab injection) for wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), d
- Pixium Vision Announces Regulatory Approval of Remote Rehabilitation System for Patients in Clinical Trialshttps://modernod.com/news/pixium-vision-announces-regulatory-approval-of-remote-rehabilitation-system-for-patients-in-clinical-trials/2481010/Pixium Vision announced the approval of the remote rehabilitation system for patients enrolled in the PRIMAvera pivotal trial and the French Feasibility Study in atrophic dry age-related macular degeneration (AMD). The approval was granted by the Ethics Commitee and the Regulatory Autho
- LumiThera Purchases MacuLogix Assetshttps://modernod.com/news/lumithera-purchases-maculogix-assets/2481007/LumiThera announced the purchase of the assets of MacuLogix. Terms of the deal were not disclosed. MacuLogix is the developer of the wearable AdaptDX Pro dark adaptometer, which allows eye care professionals to measure dark adaptation—designed to dia
- Aerie Pharmaceuticals Announces First Patient Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aerie-pharmaceuticals-announces-first-participant-dosed-in-the-comet-3-study-of-ar-15512-for-the-treatment-of-dry-eye-disease/2481006/Aerie Pharmaceuticals announced that the first participant has been dosed in the phase 3 registrational “COMET-3” study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED). COMET-3 is the second of three trials in the p